TYK2 and psoriasis vulgaris: In support of this, the first selective TYK2 inhibitor, deucravacitinib, is for the treatment of plaque psoriasis, with ongoing clinical trials in psoriatic arthritis, SLE, Crohn's disease, and ulcerative colitis.